ArticleJournal of Cancer2022

Sex differences in hepatocellular carcinoma indicated BEX4 as a potential target to improve efficacy of lenvatinib plus immune checkpoint inhibitors.

Lu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.